A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

Summary

The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination.

Timeline

Start

2021-08-27

Primary completion

2023-11-24

Completion

2023-11-24

Drugs

Indications

No indication recorded.